



Europäisches Patentamt
European Patent Office
Office européen des brevets



0 252 666 B1

(11) Publication number:

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **23.06.93** (51) Int. Cl.⁵: **C12N 15/56, C12P 19/14**
(21) Application number: **87305781.4**
(22) Date of filing: **30.06.87**

(54) Chimeric Enzymes.

(30) Priority: **30.06.86 DK 3111/86**
(43) Date of publication of application: **13.01.88 Bulletin 88/02**
(45) Publication of the grant of the patent: **23.06.93 Bulletin 93/25**
(64) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE
(56) References cited:
EP-A- 0 180 952
EP-A- 0 208 491
WO-A-85/00382
JOURNAL OF BIOCHEMISTRY Volume 98, no.5, November 1985, Tokyo Japan, pages 1147-1156; T.Yuuki et al
JOURNAL OF BIOCHEMISTRY Volume 98, no.1, July 1985, Tokyo Japan, pages 95-103; H.Ihara

(73) Proprietor: **NOVO NORDISK A/S**
Novo Allé
DK-2880 Bagsvaerd(DK)
(72) Inventor: **Diderichsen, Borge Krag**
Estersvej 32
DK-2900 Hellerup(DK)
Inventor: Outrup, Helie
Syvendehusvej 46
DK-2750 Ballerup(DK)
Inventor: Schülein, Martin
Wiedeweltsgade 51
DK-2100 Kobenhavn 0(DK)
Inventor: Norman, Barrie Edmund
Klelshoj 118
DK-3520 Farum(DK)
(74) Representative: **Brown, John David et al**
FORRESTER & BOEHMERT Franz-
Joseph-Strasse 38
W-8000 München 40 (DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to starch hydrolysing enzymes. More specifically, the present invention is directed to chimeric alpha-amylases, to processes for preparing such chimeric alpha-amylases and to the 5 use thereof for the overall enzymatic conversion of starch into high DX syrups, the term DX meaning percentage by weight of dextrose (D-glucose) calculated on the basis of dry substance (DS) of the syrup.

2. BACKGROUND OF THE INVENTION

10 The overall enzymatic process generally adopted by manufacturers of high DX syrups from starch entails two-stages: liquefaction and saccharification. The first step, the liquefaction, involves the hydrolysis of starch into a mixture of oligosaccharides, the so called maltodextrins. This process is catalyzed by alpha-amylases at a temperature of at least 75 °C, preferably at about 90 °C or by a jet-cooking process wherein the starch slurry is heated for at least several minutes to 105-110 °C, usually with a single dose of alpha-amylase, and then held at about 90 °C for at least one hour.

15 A variety of microbial, particularly bacterial, alpha-amylases are commercially available for the liquefaction process, for example BAN™ (from Bacillus amyloliquefaciens and TERMAMYL® (from Bacillus licheniformis), both supplied by NOVO INDUSTRI A/S, Denmark, and THERMOLASE™ (from Bacillus stearothermophilus) available from Enzyme Development Corporation, N.Y., U.S.A. While BAN alpha-

20 amylose is only stable up to about 85 °C and hence barely suitable for the jet-cooking process, both the TERMAMYL and THERMOLASE enzymes are well adapted for this almost globally preferred mode of starch liquefaction because they are heat stable.

The saccharification step, in which the maltodextrins are converted into dextrose, is mostly catalyzed by a glucoamylase enzyme. Commercial glucoamylase preparations, usually derived from Aspergillus or 25 Rhizopus species, are available from various manufacturers, e.g. as AMG™ 200L, a product obtained from Aspergillus niger and manufactured by NOVO INDUSTRI A/S, Denmark.

30 With a view to further increasing the dextrose yield from 30 - 40 percent by weight DS maltodextrin solutions it has become customary to conduct the saccharification process with glucoamylase in the presence of a debranching enzyme in order to facilitate the hydrolysis of branched oligosaccharides originating from the amylopectin portion of starch. One such debranching enzyme with maximum activity in the same pH and temperature ranges as glucoamylase is disclosed in European Patent Application No. 82302001.1 (Publication No. 0063909). The debranching enzyme is marketed by NOVO INDUSTRI A/S, Denmark, either as such under the proprietary name, PROMOZYME, or as a composition with suitable admixture of glucoamylase under the proprietary name DEXTROZYME.

35 Unfortunately, the otherwise very favorable combination of B. licheniformis alpha-amylase for liquefaction and glucoamylase-PROMOZYME for saccharification in the conversion of starch to high DX syrups entails an inconvenience. It has been observed that the presence of residual alpha-amylase activity from the liquefaction stage has a negative effect on the maximum DX obtainable by saccharification with glucoamylase-PROMOZYME. The problem is greatest with the thermostable B. licheniformis alphaamylase 40 which is still active at the preferred conditions for saccharification (of about pH 4.6 and temperature of about 60 °C, respectively). A remedy has been devised consisting of inactivation of the alpha-amylase prior to saccharification by acidification of the liquefied starch to a pH below 4.5 while maintaining a temperature of at least 90 °C. Following inactivation of the alpha-amylase, the temperature and pH are adjusted to saccharification conditions, meaning that the pH has to be brought up to about 4.5. This additional pH 45 adjustment inevitably increases the salt content of the syrup and hence the expenses connected with desalting the final syrup.

The object of the present invention is to overcome the above-mentioned inconveniences still associated with the use of B. licheniformis alpha-amylase for the conversion of starch into a high DX syrup. This and other objects which will be dealt with subsequently in this specification are attained by conducting the 50 liquefaction process with a novel type of alpha-amylase.

3. SUMMARY OF THE INVENTION

The chimeric alpha-amylase enzymes of the invention comprise all or portions of the amino terminus of 55 the alpha-amylase derived from B. amyloliquefaciens joined to the carboxy terminus of the alpha-amylase derived from B. licheniformis. Briefly stated, the present invention provides chimeric alpha-amylases, which are thermostable and exhibit a reduced negative effect on the use of A. niger glucoamylase and B. acidopullulyticus pullulanase for the saccharification of starch, having the general formula I


(I)
Q-R-L

5 in which Q is a N-terminal part of from 55 to 60 amino acid residues which is at least 75 percent, preferably at least 80 percent, and more preferably at least 90 percent homologous to the 57 N-terminal amino acid residues in the Bacillus amyloliquefaciens alpha-amylase (Takkinen, et al., 1983, J.Biol.Chem. 258:1007-1013);

R is a part of the general formula Ia:


10

(Ia)



15

20



25

in which

X₈ is His or Gln,
X₉ is Gly or Ser,
30 X₁₀ is Ser or Asp; and

L is a C-terminal part of from 390 to 400 amino acid residues which is at least 75 percent, preferably at least 80 percent, and more preferably at least 90 percent homologous to the 395 C-terminal amino acid residues in the Bacillus licheniformis 584 (ATCC 27811) alpha-amylase (Stephens et al., 1984, J.Bacteriol. 158:369-372).

35

Because of the relevance of Takkinen et al., *supra*, and Stephens et al., *supra*, in defining the amino acid sequences of the alpha amylases produced by B. amyloliquefaciens and B. licheniformis, portions of which sequences are contained within the chimeric amylases of the invention, these references are incorporated by reference herein in their entirety.

40

The amino acid sequence of the chimeric enzymes described and shown above may be modified by the substitution, deletion or addition of amino acid residues within the sequence which result in a silent change in the molecule so that the product retains its activity. Such amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. For example, acidic amino acids (negatively charged at pH 6.0) include aspartic acid and glutamic acid; basic amino acids (positively charged at pH 6.0) include lysine and arginine; amino acids with uncharged polar head groups or nonpolar head groups having similar hydrophilic properties include the following: leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine; phenylalanine, tyrosine.

45

In another aspect the invention relates to processes for the production of the novel amylase of the first aspect above. According to this second aspect the amylases of the invention may be produced by the use of conventional genetic engineering techniques, such as gene splicing or by use of *in vivo* recombination to be described below, or by chemical synthetic techniques.

In a third aspect the invention relates to the use of the chimeric amylases in the liquefaction stage in the production of high DX syrups, especially in the jet cooking process mentioned above.

50

The chimeric alpha-amylases upon which the invention is based surprisingly demonstrate the excellent thermostability characteristics of alpha-amylase derived from B. licheniformis, but at the same time a reduced negative effect on the maximum obtainable DX without being inactivated prior to the saccharification. The invention is demonstrated herein, by way of examples, in which a segment of B. licheniformis alpha-amylase consisting of from about amino acid residue number 57 to about amino acid

X₃ is Ser-Ala-Tyr or Ala-Glu-His,
X₄ is Ala-Glu-His or Ser-Asp-Ile,
X₅ is Thr or Leu,
X₆ is Ala or Ser,
5 X₇ is Val or Asn; and

R and L are defined as previously in Section 3 supra.

In another preferred alpha-amylase of the general formula I, Q and R are defined as previously described, and L is a C-terminal part of the general formula Ic

10

(Ic)

	90	95	100
	Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val-		
15	105	110	115
	Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-		
	120	125	130
20	Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-		
	135	140	145
	Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Phe-Pro-Gly-Arg-		
25	150	155	160
	Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-		
	165	170	175
30	Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-		
	180	185	190
	Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-		

35

40

45

50

55

	195	200	205
	Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-		
5	210	215	220
	Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-		
	225	230	235
10	Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-		
	240	245	250
	Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-		
	255	260	265
15	Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-		
	270	275	280
	Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-		
	285	290	295
20	Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-		
	300	305	319
	Thr-Gln-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-		
	315	320	325
25	Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-		
	330	335	340
	His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-		
30	345	350	355
	Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-		
	360	365	370
35	Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-		
	375	380	385
	Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-		
	390	395	400
40	Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-		
	405	410	415
	Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-		
	420	425	430
45	Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-		
	435	440	445
	Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-		

450 455 460
Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pr-Val-Val-
 465 470 475
⁵ **Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-**
 480 483
Val-Ser-Ile-Tyr-Val-Gln-Arg

¹⁰ In still another preferred alpha-amylase of the general formula I, Q has the general formula Ib and L is a C-terminal part of the general formula Ic, in which X₁ is Val, X₂ is Thr, X₃ is Ala-Glu-His, X₄ is Ser-Asp-Ile, X₅ is Leu, X₆ is Ser, and X₇ is Asn.

¹⁵ In yet another preferred alpha-amylase of the general formula I, Q has the general formula Ib in which X₁ is Val, X₂ is Thr, X₃ is Ala-Glu-His, X₄ is Ser-Asp-Ile, X₅ is Leu, X₆ is Ser, and X₇ is Asn; L is a C-terminal peptide residue of the general formula Ic; and amino acid residues X₈, X₉, and X₁₀ of R are Gln, Ser and Asp, respectively.

²⁰ In yet another preferred alpha-amylase of the general formula I, Q has the general formula Ib in which Q, X₁ is Val, X₂ is Thr, X₃ is Ala-Glu-His, X₄ is Ser-Asp-Ile, X₅ is Leu, X₆ is Ser, and X₇ is Asn; L is a C-terminal part of the general formula Ic; and amino acid residues X₈, X₉ and X₁₀ of R are His, Gly and Ser, respectively.

5.2 METHODS FOR PRODUCING THE CHIMERIC AMYLASES

²⁵ The amylases of the invention are chimeric enzymes and may in accordance with the second aspect of the invention be produced in a number of ways as described below.

³⁰ Naturally occurring enzymes may be genetically modified by random or site directed mutagenesis. Alternatively, part of one enzyme may be replaced by a part of another to obtain a chimeric enzyme. This replacement can be achieved either by conventional *in vitro* gene splicing techniques or by *in vivo* recombination or by combinations of both techniques. When using conventional *in vitro* gene splicing techniques, a desired portion of the alpha-amylase gene coding sequence may be deleted using appropriate site-specific restriction enzymes; the deleted portion of the coding sequence may then be replaced by the insertion of a desired portion of a different alpha-amylase coding sequence so that a chimeric nucleotide sequence encoding a new alpha-amylase is produced.

³⁵ The *in vivo* recombinant techniques depend on the fact that different DNA segments with highly homologous regions (identity of DNA sequence) may recombine, i.e. break and exchange DNA, and establish new bonds in the homologous regions. Accordingly, when the coding sequences for two different but homologous amylase enzymes are used to transform a host cell, recombination of homologous sequences *in vivo* will result in the production of chimeric gene sequences. Translation of these coding sequences by the host cell will result in production of a chimeric amylase gene product.

The alpha-amylase genes from *Bacillus licheniformis* (herein designated *amyL*) and from *Bacillus amyloliquefaciens* (herein designated *amyQ*) are approximately 70 percent homologous at the DNA level and suitable for hybrid formation by *in vivo* gene splicing.

⁴⁵ In an alternate embodiment, the chimeric enzyme may be synthesized by standard chemical methods known in the art. For example, see Hunkapiller et al., 1984, *Nature* 310:105-111. Accordingly, peptides having the amino acid sequences described *supra* may be synthesized in whole or in part and joined to form the chimeric enzymes of the invention.

5.3 USES OF THE CHIMERIC AMYLASES

⁵⁰ According to its third aspect the invention relates to the use of the novel alpha-amylases in the liquefaction stage in the overall enzymatic conversion of starch into high DX syrups.

As indicated previously residual activity from the use of the thermostable alpha-amylase from *B. licheniformis* in the liquefaction stage entails a negative effect on maximum obtainable D-glucose yield in the saccharification stage when using *A. niger* glucoamylase and *B. acidopullulyticus* pullulanase.

The reason for this negative effect is not fully understood, but it is assumed that *B. licheniformis* alpha-amylase generates "limit dextrans" which are poor substrates for *B. acidopullulyticus* pullulanase, by hydrolyzing 1, 4-alpha-glucosidic linkages close to the branch-points in amylopectin. These limit dextrans

which contain too few glucose units in one or more of the side chains will be less susceptible to B. acidopullulyticus pullulanase attack.

In FIG. 1 the action patterns for B. licheniformis alpha-amylase, B. amyloliquefaciens alpha-amylase, and the hybrid QL1864 alpha-amylase on amylopectin are indicated by the gel-permeation chromatograms taken from amylopectin digests after 48 hours.

From the figure it is seen that the action pattern of B. licheniformis alpha-amylase on amylopectin is different from that of B. amyloliquefaciens alpha-amylase. The B. licheniformis enzyme produces mainly DP₆, DP₅ and DP₃ initially. On prolonged hydrolysis the DP₆ fraction is hydrolyzed further, and the major components are DP₅, DP₃, and DP₂. When B. amyloliquefaciens alpha-amylase is used the major components are DP₆.

The action pattern of the alpha-amylases of the invention as exemplified by the QL1864 alpha-amylase on amylopectin is distinctly different from both naturally occurring alpha-amylases, and as shown below, this changed action pattern surprisingly has resulted in the removal of the negative effect from B. licheniformis alpha-amylase on the D-glucose yield, while retaining the thermostability.

Accordingly it has been found that the alpha-amylases of the invention are very efficiently used for the liquefaction of starch.

6. EXAMPLE: CHIMERIC AMYLASE QL1864

The subsections below describe the production and characterization of the chimeric alpha-amylase QL1864.

6.1. CONSTRUCTION OF HYBRID QL1864

By conventional techniques, amyL and amyQ were cloned in B. subtilis. The restriction enzyme map of the two genes were in agreement with published DNA sequences for the genes for B. licheniformis amylase (amyL) (Stephens et al. 1986, J. Bacteriol. 158: 369 (1984)) and B. amyloliquefaciens amylase (amyQ) (Takkinen et al., 1983, J. Biol. Chem 258: 1007) 1983), respectively.

amyQ (amyQ+) and a C-terminal part of amyL (amyL-) were placed in parallel on plasmid pDN1822. This is a B. subtilis plasmid derived from cloning vector pUB110 and harbouring the chloramphenicol resistance (Cam^R) gene (cat gene) of cloning vector pC194. The restriction map of pDN1822 is shown in FIG. 2, where the genes are indicated by arrows. The C-terminal part of amyQ on pDN1822 was then deleted by excision of a PvuI-PvuI fragment, which is shown hatched in FIG. 2, to obtain plasmid pDN1850 (FIG. 3). pDN1850 is amylase negative (Amy-) but harbors a N-terminal-part of amyQ and a C-terminal part of amyL. However, with a frequency of about 10⁻⁴, recombination between amyQ and amyL occurs resulting in the plasmids harbouring a hybrid QL amylase gene (amyQL+) and of an amylase positive phenotype (Amy+).

Transformation with a plasmid preparation of pDN1850 into a plasmid free B. subtilis recipient selecting for Cam^R on starch containing agar plates resulted in about 1:10⁴ transformants producing an active amylase. These transformants were surrounded by a halo of degraded starch which could be identified by iodine vapour. These Amy⁺ transformants harboured a QL hybrid amylase gene on the plasmid. From these transformants the plasmids pDN1851 to pDN1865 were isolated, and it was found that transformants containing plasmids pDN1851, pDN1858 to pDN1862 and pDN1864 produced alpha-amylases that fulfill the objects of the invention. By restriction enzyme mapping of plasmid pDN1864, the amyQ/L1864 gene was characterized (FIG. 4) and shown to harbor an Avall site from amyQ, but not the nearby EcoRI site from amyQ. Hence, recombination between amyQ and amyL as indicated by the cross-hatched area in FIG. 3 took place between the codons coding for amino acid No. 58 and No. 67 in the B. licheniformis alpha-amylase. B. subtilis QL1864 is therefore producing a chimeric amylase composed of about 1/6 amyQ amylase at the N-terminal end and about 5/6 amyL amylase at the C-terminal end.

6.2 ANALYSIS OF CHIMERIC AMYLASE PRODUCED BY QL1864

In the following tests the enzyme units used are defined as indicated below:

One NU (NOVO Unit) of alpha-amylase activity is the amount of enzyme which breaks down 5.26 mg of dissolved starch per hour at 37 °C, pH 5.6 and 0.0043 M of Ca⁺⁺ over a 7-20 minute reaction time.

One AG unit of glucoamylase activity is the amount of enzyme which hydrolyzes one micromole of maltose per minute at 25 °C and pH 4.3.

One pullulanase unit (PUN) is defined as the amount of enzyme which under standard conditions (temperature 40 °C and pH 5.0) hydrolyzes pullulan at a rate corresponding to the formation of reducing groups equivalent to 1 μmole of glucose per minute.

5 6.2.1. SACCHARIFICATION TEST OF CHIMERIC AMYLASE

As explained above it has been found that the presence of a residual B. licheniformis alpha-amylase activity originating from the liquefaction stage has a negative effect on maximum D-glucose yield in the saccharification stage when B. acidopullulyticus pullulanase and A. niger glucoamylase are used in combination.

In order to evaluate the influence of a residual activity from the chimeric alpha-amylases of the invention on the saccharification stage they were compared to the B. licheniformis alpha-amylase in the following way:

Substrates for saccharification were prepared by redissolving a DE 8 spray-dried maltodextrin (APS 840964A) in deionized water the making up to approximately 30% DS (dry substance). Saccharification experiments were carried out in standard 500 ml laboratory batch reactions.

pH's were measured at saccharification temperature with the pH electrode and pH meter calibrated and adjusted in buffer at 60 °C.

The following standard conditions were used:

20

25

Substrate concentration	28.2% (initial)	30.8% (final)
Temperature	60 °C	
pH (initial, at 60 °C)	4.6	
Enzyme dosage:		
glucoamylase	0.15 AG/g DS	
pullulanase	0.33 PUN/g DS	
alpha-amylase	60 NU/g DS	

30

35

40

45

50

55

The results of the tests are presented in Table I

TABLE I
SACCHARIFICATION TEST OF CHIMERIC AMYLASE

Alpha-Amylase	Reaction		Conditions				
	time	(h)	pH	\$DP₁	\$DP₂	\$DP₃	\$DP₄
				\$DP₁	\$DP₂	\$DP₃	\$DP₄
None	24	4.5	92.8	2.5	1.1	3.6	
(Control)	48	4.4	96.7	1.8	0.7	0.8	
	72	4.4	96.8	2.0	0.6	0.6	
	96	4.4	96.8	2.2	0.5	0.5	
B. licheniformis	24	4.5	92.4	2.5	2.4	2.7	
	48	4.5	95.9	1.8	1.5	0.9	
	72	4.4	96.2	2.0	1.1	0.7	
	96	4.4	96.4	2.1	0.9	0.6	
QL 1864	24	4.6	92.1	2.8	1.9	3.2	
	48	4.5	96.3	1.7	1.2	0.9	
	72	4.5	96.5	2.0	0.9	0.7	
	96	4.5	96.6	2.1	0.8	0.6	

From the results shown in Table I it is seen that although the presence of QL 1864 alpha-amylase slightly reduced the maximum obtainable DX (in comparison to the control), it represents a significant improvement over the B. licheniformis alpha-amylase.

6.2.2 THERMOACTIVATION OF CHIMERIC AMYLASE

In order to evaluate the thermoactivation of the chimeric alpha-amylases produced by the transformed strains the chimeric alpha-amylases were submitted to the following test:

Substrate: Phadebas tablets (Phadebas® amylase test, Pharmacia Diagnostics, Sweden) a cross-linked blue coloured starch polymer insoluble in water.

Buffer: 0.1 M phosphate, pH 6.1, and TRIS buffer pH 9.5.

Enzyme: alpha-Amylase diluted to 1-2 NU/ml in 0.09 M CaCl₂, pH 6.1.

Temperatures: 37°C and 85°C

1 ml alpha-amylase dilution was thoroughly mixed with 5 ml buffer and incubated in a water bath at the desired temperature prior to the addition of one Phadebas tablet.

The test tube was shaken for 15 seconds on a whirl mixer before it is placed in the water bath again.

After exactly 15 minutes the reaction was stopped by the addition of 1 ml 1 M NaOH. After mixing the mixture was filtered through a 9 cm Whatman® GF/A or FG/C filter.

The optical density of the filtrate was measured at a wavelength of 620 nm, and was found to be linearly related to the activity of alpha-amylase added.

The results are presented in Table II below together with values from tests with pure B. licheniformis and B. amyloliquefaciens alpha-amylases.

TABLE II
THERMOACTIVATION OF CHIMERIC AMYLASE

<u>Alpha-Amylase</u>	Phadebas 37°C	Phadebas pH 6.1
	pH 6.1:pH 9.5	75°C:37°C
<u>B. licheniformis</u>	0.4	3.7
(control)		
QL1864	2.5	2.5
QL1861	2.2	2.2
QL1851	2.1	2.1
QL1862	2.0	2.0
QL1858	2.0	2.0
<u>B. amyloliquefaciens</u>	8.7	0.01
(control)		

The data presented in Table II demonstrate that the chimeric alpha-amylases of the invention are as thermoactivated as the B. licheniformis alpha-amylase, and less sensitive to alkaline pH than the B. amyloliquefaciens alpha-amylase.

6.2.3. THERMOSTABILITY OF CHIMERIC AMYLASE

In order to evaluate the stability of the alpha-amylases of the invention the following steel tube tests were performed:

A DE 7 maltodextrin redissolved in deionized water was used as substrate under the following conditions:

Substrate: 32 - 33 percent
alpha-amylase dosage: 120 NU/g maltodextrin
Temperature: 105°C
pH: 5.5
Calcium content: 60 ppm

In each test 5 steel tubes containing the above reaction mixture were placed in an oil bath at 105°C and taken out after 10, 20, 30, 40, and 60 minutes, respectively, and the residual alpha-amylase activity measured by the Phadebas method described above. The half life, $T_{1/2}$, is calculated by linear regression of log (residual activity) versus time. The results are shown in Table III below.

45

TABLE III

THERMOSTABILITY OF CHIMERIC AMYLASES	
Alpha-Amylase	$T_{1/2}$ minutes
<u>B. amyloliquefaciens</u> (control)	5
QL 1851	22
QL 1858	25
QL 1861	18
QL 1862	22
QL 1864	24
<u>B. licheniformis</u> (control)	23

From the results shown in Table III it is clearly seen that the hybrid alpha-amylases of the invention have retained the stability of the B. licheniformis alpha-amylase.

Claims

5 Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A chimeric alpha-amylase, which is thermostable and exhibits a reduced negative effect on the use of A. niger glucoamylase and B. acidopolulyticus pullulanase for the saccharification of starch, having the general formula I

10

(I)

Q-R-L

15

in which Q comprises a N-terminal part of from 55 to 60 amino acid residues which is at least 75% homologous to the 55 N-terminal amino acid residues in the Bacillus amyloliquefaciens alpha-amylase as described in Takkinen et al., J. Biol. Chem. 258 (1983) 1007-1013;

R comprises a part of the general formula Ia

20

(Ia)

58

60

70

Pro-Tyr-Asp-Leu-Tyr-Asp-Leu-Gly-Glu-Phe-X₈-Gln-Lys-

25

80

Gly-Thr-Val-Arg-Thr-Lys-Tyr-Gly-Thr-Lys-X₉-Glu-Leu

88

30

Gln-X₁₀-Ala-Ile-Lys

in which

X₈ comprises His or Gln,

35

X₉ comprises Gly or Ser,

X₁₀ comprises Ser or Asp; and

L comprises a C-terminal part of from 390 to 400 amino acid residues which is at least 75% homologous to the 395 C-terminal amino acid residues in the Bacillus licheniformis 584 (ATCC 27811) alpha-amylase.

40

2. The chimeric alpha-amylase according to claim 1, in which

X₈ comprises His,

X₉ comprises Gly, and

X₁₀ comprises Ser.

45

3. The chimeric alpha-amylase according to claim 1, in which

X₈ comprises Gln,

X₉ comprises Ser, and

X₁₀ comprises Asp.

50

4. The chimeric alpha-amylase according to claim 1, in which the homologies are at least 80 percent.

5. The chimeric alpha-amylase according to claim 1, in which the homologies are at least 90 percent.

55

6. The chimeric alpha-amylase according to claim 1, in which Q comprises an N-terminal part of the general formula Ib

(Ib)

5 10 15

5 X_1 -Asn-Gly-Thr-Leu-Met-Gln-Tyr-Phe-Glu-Trp-Tyr- X_2 -Pro-Asn-

20 25 30 35

Asp-Gly-Gln-His-Trp-Lys-Arg-Leu-Gln-Asn-Asp- X_3 -Leu- X_4 -Gly-

10 40 45 50

Ile-Thr-Ala-Val-Trp-Ile-Pro-Pro-Ala-Tyr-Lys-Gly- X_5 -Ser-Gln-

55

15 X_6 -Asp- X_7 -Gly-Tyr-Gly;

in which

- 20 X_1 comprises Ala-Asn-Leu or Val,
- X_2 comprises Met or Thr,
- X_3 comprises Ser-Ala-Tyr or Ala-Glu-His,
- X_4 comprises Ala-Gly-His or Ser-Asp-Ile,
- X_5 comprises Thr or Leu,
- X_6 comprises Ala or Ser, and
- X_7 comprises Val or Asn.

25 7. The chimeric alpha-amylase according to claim 6, in which

- X_1 comprises Val,
- X_2 comprises Thr,
- X_3 comprises Ala-Glu-His,
- 30 X_4 comprises Ser-Asp-Ile,
- X_5 comprises Leu,
- X_6 comprises Ser, and
- X_7 comprises Asn.

35 8. The alpha-amylase according to claim 4, 5, 6, or 7, in which L comprises a C-terminal part of the general formula Ic

40

45

50

55

(Ic)

90 95 100
Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val

5 105 110 115
Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-

10 120 125 130
Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-

15 135 140 145
Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Phe-Pro-Gly-Arg-

20 150 155 160
Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-

25 165 170 175
Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-

30 180 185 190
Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-

35 195 200 205
Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-

40 210 215 220
Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-

45 225 230 235
Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-

50 240 245 250
Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-

55 255 260 265
Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-

60 270 275 280
Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-

65 285 290 285
Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-

70 300 305 310
Thr-Gln-Gly-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-

315 320 325
Val-Val-S r-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-

330 335 340
⁵ **His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-**

345 350 355
Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-

10 360 365 370
Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-

375 380 385
¹⁵ **Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-**

390 395 400
Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-

405 410 415
²⁰ **Tyr-Phe-Asp-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-**

420 425 430
Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-

435 440 445
²⁵ **Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-**

450 455 460
Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-

465 470 475
³⁰ **Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-**

480 483
³⁵ **Val-Ser-Ile-Tyr-Val-Gln-Arg.**

9. A process for the production of a chimeric alpha-amylase comprising:

(a) recombining in vivo the N-terminal coding region of the alpha-amylase gene of B. amyloliquefaciens with the C-terminal coding region of the alpha-amylase gene of B. licheniformis to form recombinants;

(b) selecting the recombinants that produce a chimeric alpha-amylase that is thermostable and exhibits a reduced negative effect on the use of A. niger glucoamylase and B. acidopullulyticus pullulanase for the saccharification of starch;

(c) culturing the selected recombinants in an appropriate growth medium, and

(d) recovering the chimeric alpha-amylase from the culture.

10. A process for converting starch into high dextrose syrup, comprising:

(a) reacting the starch with the chimeric alpha-amylase of claim 1, 2, 3, 4, 5, 6, or 7 to form oligosaccharides; and

(b) reacting the oligosaccharides formed in step (a) with a glucoamylase to form dextrose.

11. A process for converting starch into high dextrose syrup, comprising:

(a) reacting the starch with the chimeric alpha-amylase of claim 8 to form oligosaccharides; and

(b) reacting the oligosaccharides formed in step (a) with a glucoamylase to form dextrose.

Claims for the following Contracting States : AT, ES, GR

1. A process for the production of a chimeric alpha-amylase comprising:

(a) recombining in vivo the N-terminal coding region of the alpha-amylase gene of B. amyloliquefaciens with the C-terminal coding region of the alpha-amylase gene of B. licheniformis to form recombinants;

(b) selecting the recombinants that produce a chimeric alpha-amylase that is thermostable and exhibits a reduced negative effect on the use of A. niger glucoamylase and B. acidopullulyticus pullulanase for the saccharification of starch;

(c) culturing the selected recombinants in an appropriate growth medium, and

(d) recovering the chimeric alpha-amylase from the culture.

2. A process for converting starch into high dextrose syrup, comprising:

(a) reacting the starch with a chimeric alpha-amylase, which is thermostable and exhibits a reduced negative effect on the use of A. niger glucoamylase and B. acidopullulyticus pullulanase for the saccharification of starch, having the general formula I


(I)

Q-R-L

in which Q comprises a N-terminal part of from 55 to 60 amino acid residues which is at least 75% homologous to the 55 N-terminal amino acid residues in the Bacillus amyloliquefaciens alpha-amylase as described in Takkinen et al., J. Biol. Chem. 258 (1983) 1007-1013;

R comprises a part of the general formula Ia

(Ia)



40 in which

X₈ comprises His or Gln,

X₉ comprises Gly or Ser,

X₁₀ comprises Ser or Asp; and

45 L comprises a C-terminal part of from 390 to 400 amino acid residues which is at least 75% homologous to the 395 C-terminal amino acid residues in the Bacillus licheniformis 584 (ATCC 27811) alpha-amylase, to form oligosaccharides; and
 (b) reacting the oligosaccharides formed in step (a) with a glucoamylase to form dextrose.

50 3. A process according to Claim 2, wherein, in the chimeric alpha-amylase,

X₈ comprises His,

X₉ comprises Gly, and

X₁₀ comprises Ser.

55 4. A process according to Claim 2, wherein, in the chimeric alpha-amylase

X₈ comprises Gln,

X₉ comprises Ser, and

X₁₀ comprises Asp.

(Ic)

90 95 100
Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val

5 105 110 115
Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-

10 120 125 130
Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-

15 135 140 145
Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Phe-Pro-Gly-Arg-

20 150 155 160
Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-

25 165 170 175
Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-

30 180 185 190
Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-

35 195 200 205
Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-

40 210 215 220
Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-

45 225 230 235
Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-

50 240 245 250
Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-

55 255 260 265
Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-

60 270 275 280
Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-

65 285 290 285
Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-

70 300 305 310
Thr-Gln-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-

315 320 325
Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-

330 335 340
⁵ **His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-**

345 350 355
Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-

10 360 365 370
Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-

375 380 385
¹⁵ **Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-**

390 395 400
Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-

405 410 415
²⁰ **Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-**

420 425 430
Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-

435 440 445
²⁵ **Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-**

450 455 460
Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-

30 465 470 475
Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-

480 483
³⁵ **Val-Ser-Ile-Tyr-Val-Gln-Arg.**

Patentansprüche**40 Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Chimäre Alpha-Amylase, die hitzestabil ist und eine verringerte negative Wirkung auf die Verwendung von Glucoamylase aus A. niger und Pullulanase aus B. acidopullulolyticus zur Verzuckerung von Stärke zeigt, mit der allgemeinen Formel I

45

(I)

Q-R-L,

50

in der Q eine N-terminalen Teil mit von 55 bis 60 Aminosäureresten umfaßt, der wenigstens 75% homolog zu den 55 N-terminalen Aminosäureresten in der Alpha-Amylase aus Bacillus amyloliquefaciens ist, wie in Takkinen et al., J. Biol. Chem. 258 (1983), 1007-1013 beschrieben; R einen Teil der allgemeinen Formel Ia umfaßt

55

(Ia)

in der

X₈ His oder Gln umfaßt,
 X₉ Gly oder Ser umfaßt,
 X₁₀ Ser oder Asp umfaßt; und

20 L einen C-terminalen Teil mit von 390 bis 400 Aminosäureresten umfaßt, der wenigstens 75% homolog zu den 395 C-terminalen Aminosäureresten in der Alpha-Amylase aus Bacillus licheniformis 584 (ATCC 27811) ist.

2. Chimäre Alpha-Amylase nach Anspruch 1, in der
 - X₈ His umfaßt,
 - X₉ Gly umfaßt, und
 - X₁₀ Ser umfaßt.
3. Chimäre Alpha-Amylase nach Anspruch 1, in der
 - X₈ Gln umfaßt,
 - X₉ Ser umfaßt und
 - X₁₀ Asp umfaßt.
4. Chimäre Alpha-Amylase nach Anspruch 1, in der die Homologien wenigstens 80 Prozent sind.
5. Chimäre Alpha-Amylase nach Anspruch 1, in der die Homologien wenigstens 90 Prozent sind.
6. Chimäre Alpha-Amylase nach Anspruch 1, in der Q einen N-terminalen Teil der allgemeinen Formel Ib umfaßt

(Tb)

5 10 15
 45 X_1 -Asn-Gly-Thr-Leu-Met-Gln-Tyr-Phe-Glu-Trp-Tyr- X_2 -Pro-Asn-
 20 25 30 35
 Asp-Gly-Gln-His-Trp-Lys-Arg-Leu-Gln-Asn-Asp- X_3 -Leu- X_4 -Gly-
 50 40 45 50
 Ile-Thr-Ala-Val-Trp-Ile-Pro-Pro-Ala-Tyr-Lys-Gly- X_5 -Ser-Gln-
 55
 X_6 -Asp- X_7 -Gly-Tyr-Gly;

in der

X₁ Ala-Asn-Leu oder Val umfaßt,

X₂ Met oder Thr umfaßt,
X₃ Ser-Ala-Tyr oder Ala-Glu-His umfaßt,
X₄ Ala-Gly-His oder Ser-Asp-Ile umfaßt,
X₅ Thr oder Leu umfaßt,
5 X₆ Ala oder Ser umfaßt und
X₇ Val oder Asn umfaßt.

7. Chimäre Alpha-Amylase nach Anspruch 6, in der
10 X₁ Val umfaßt,
X₂ Thr umfaßt,
X₃ Ala-Glu-His umfaßt,
X₄ Ser-Asp-Ile umfaßt,
X₅ Leu umfaßt,
X₆ Ser umfaßt und
15 X₇ Asn umfaßt.

8. Alpha-Amylase nach Anspruch 4, 5, 6 oder 7, in der L einen C-terminalen Teil der allgemeinen Formel
Ic umfaßt

20 (Ic)

25 90 95 100
Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val

30 105 110 115
Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-

35 120 125 130
Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-

40 135 140 145
Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Pro-Gly-Arg-

45 150 155 160
Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-

50 165 170 175
Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-

45

50

55

180 185 190
 Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-
 195 200 205
 Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-
 210 215 220
 Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-
 225 230 235
 Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-
 240 245 250
 Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-
 255 260 265
 Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-
 270 275 280
 Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-
 285 290 285
 Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-
 300 305 310
 Thr-Gln-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-
 315 320 325
 Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-
 330 335 340
 His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-
 345 350 355
 Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-
 360 365 370
 Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-
 375 380 385
 Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-
 390 395 400
 Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-
 405 410 415
 Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-
 420 425 430
 Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-
 435 440 445
 Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-

450 455 460
Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-
465 470 475
5 Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-
480 483
Val-Ser-Ile-Tyr-Val-Gln-Arg.

10

9. Verfahren zur Herstellung einer chimären Alpha-Amylase, welches umfaßt:

(a) daß die N-terminale Kodierungsregion des Alpha-Amylase-Gens von B. amyloliquefaciens mit der C-terminalen Kodierungsregion des Alpha-Amylase-Gens von B. licheniformis in vivo rekombiniert wird, um Rekombinanter zu bilden;
(b) daß die Rekombinanter, die eine chimäre Alpha-Amylase produzieren, die hitzestabil ist und eine verringerte negative Wirkung auf die Verwendung von Glucoamylase aus A. niger und Pullulanase aus B. acidopullulyticus zur Verzuckerung von Stärke zeigt, selektiert werden;
(c) daß die selektierten Rekombinanter in einem geeigneten Wachstumsmedium kultiviert werden und
(d) daß die chimäre Alpha-Amylase aus der Kultur gewonnen wird.

10. Verfahren zur Umwandlung von Stärke in High-Dextrose-Sirup, welches umfaßt:

(a) daß die Stärke mit der chimären Alpha-Amylase von Anspruch 1, 2, 3, 4, 5, 6 oder 7 zur Reaktion gebracht wird, um Oligosaccharide zu bilden; und
(b) daß die in Schritt (a) gebildeten Oligosaccharide mit einer Glucoamylase zur Reaktion gebracht werden, um Dextrose zu bilden.

11. Verfahren zur Umwandlung von Stärke in High-Dextrose-Sirup, welches umfaßt:

(a) daß die Stärke mit der chimären Alpha-Amylase von Anspruch 8 zur Reaktion gebracht wird, um Oligosaccharide zu bilden; und
(b) daß die in Schritt (a) gebildeten Oligosaccharide mit einer Glucoamylase zur Reaktion gebracht werden, um Dextrose zu bilden.

35 Patentansprüche für folgende Vertragsstaaten : AT, ES, GR

1. Verfahren zur Herstellung einer chimären Alpha-Amylase, welches umfaßt:

a) daß die N-terminale Kodierungsregion des Alpha-Amylase-Gens von B. amyloliquefaciens mit der C-terminalen Kodierungsregion des Alpha-Amylase-Gens von B. licheniformis in vivo rekombiniert wird, um Rekombinanter zu bilden;
b) daß die Rekombinanter, die eine chimäre Alpha-Amylase produzieren, die hitzestabil ist und eine verringerte negative Wirkung auf die Verwendung von Glucoamylase aus A. niger und Pullulanase aus B. acidopullulyticus zur Verzuckerung von Stärke zeigt, selektiert werden;
c) daß die selektierten Rekombinanter in einem geeigneten Wachstumsmedium kultiviert werden und
d) daß die chimäre Alpha-Amylase aus der Kultur gewonnen wird.

2. Verfahren zur Umwandlung von Stärke in High-Dextrose-Sirup, welches umfaßt:

a) daß die Stärke mit einer chimären Alpha-Amylase zur Reaktion gebracht wird, die hitzestabil ist und eine verringerte negative Wirkung auf die Verwendung von Glucoamylase aus A. niger und Pullulanase aus B. acidopullulyticus zur Verzuckerung von Stärke zeigt, mit der allgemeinen Formel I

55

(I)

Q-R-L

in der Q einen N-terminalen Teil mit von 55 bis 60 Aminosäureresten umfaßt, der wenigstens 75% homolog zu den 55 N-terminalen Aminosäureresten in der Alpha-Amylase aus Bacillus amyloliquefaciens ist, wie in Takkinnen et al., J. Biol. Chem. 258 (1983), 1007-1013 beschrieben; R einen Teil der allgemeinen Formel Ia umfaßt

5

(Ia)

10

15

20

in der

X₈ His oder Gln umfaßt.

X_s Gly oder Ser umfaßt.

X₁₀ Ser oder Asp umfaßt; und

L einen C-terminalen Teil mit von 390 bis 400 Aminosäureresten umfaßt, der wenigstens 75% homolog zu den 395 C-terminalen Aminosäureresten in der Alpha-Amylase aus Bacillus licheniformis

30

(b) daß die in Schritt (a) gebildeten Oligosaccharide mit einer Glucoamylase zur Reaktion gebracht

werden, um Dextrose zu bilden.

werden, um Beiträge zu finden.

3. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase
35 X₈ His umfaßt,
 X₉ Gly umfaßt und
 X₁₀ Ser umfaßt.

4. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase
40 X₈ Gln umfaßt,
 X₉ Ser umfaßt und
 X₁₀ Asp umfaßt.

5. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase die Homolo-
45 gien wenigstens 80% sind.

6. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase die Homolo-
50 gien wenigstens 90% sind.

7. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase Q einen N-
terminalen Teil der allgemeinen Formel Ib umfaßt

55

(Ib)

5 10 15
 X_1 -Asn-Gly-Thr-Leu-Met-Gln-Tyr-Phe-Glu-Trp-Tyr- X_2 -Pro-Asn-
20 25 30 35
Asp-Gly-Gln-His-Trp-Lys-Arg-Leu-Gln-Asn-Asp- X_3 -Leu- X_4 -Gly-
10 40 45 50
Ile-Thr-Ala-Val-Trp-Ile-Pro-Pro-Ala-Tyr-Lys-Gly- X_5 -Ser-Gln-
55
15 X_6 -Asp- X_7 -Gly-Tyr-Gly:

in der

- 20 X_1 Ala-Asn-Leu oder Val umfaßt,
- X_2 Met oder Thr umfaßt,
- X_3 Ser-Ala-Tyr oder Ala-Glu-His umfaßt,
- X_4 Ala-Gly-His oder Ser-Asp-Ile umfaßt,
- X_5 Thr oder Leu umfaßt,
- X_6 Ala oder Ser umfaßt und
- 25 X_7 Val oder Asn umfaßt.

8. Verfahren nach Anspruch 7, dadurch gekennzeichnet, daß in der chimären Alpha-Amylase

- 30 X_1 Val umfaßt,
- X_2 Thr umfaßt,
- X_3 Ala-Glu-His umfaßt,
- X_4 Ser-Asp-Ile umfaßt,
- X_5 Leu umfaßt,
- X_6 Ser umfaßt und
- 35 X_7 Asn umfaßt.

9. Verfahren zur Umwandlung von Stärke in High-Dextrose-Sirup, welches umfaßt:

- (a) daß die Stärke mit einer chimären Alpha-Amylase zur Reaktion gebracht wird, um Oligosaccharide zu bilden; und
- 40 (b) daß die in Schritt (a) gebildeten Oligosaccharide mit einer Glucoamylase zur Reaktion gebracht werden, um Dextrose zu bilden, wobei die chimäre Alpha-Amylase so ist, wie in Anspruch 5, 6, 7 oder 8 definiert, und in der L einen C-terminalen Teil der allgemeinen Formel Ic umfaßt

45

50

55

(Ic)

5 90 95 100
 Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val
 105 110 115
 10 Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-
 120 125 130
 Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-
 135 140 145
 15 Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Phe-Pro-Gly-Arg-
 150 155 160
 Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-
 20 165 170 175
 Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-
 ——————
 25 180 185 190
 Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-
 195 200 205
 Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-
 30 210 215 220
 Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-
 225 230 235
 35 Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-
 240 245 250
 Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-
 40 255 260 265
 Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-

45

50

55

270 275 280
 Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-

285 290 285
 5 Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-

300 305 310
 Thr-Gln-Gly-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-

315 320 325
 10 Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-

330 335 340
 His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-

345 350 355
 15 Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-

360 365 370
 Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-

375 380 385
 20 Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-

390 395 400
 Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-

405 410 415
 Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-

420 425 430
 25 Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-

435 440 445
 Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-

450 455 460
 30 Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-

465 470 475
 Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-

480 483
 40 Val-Ser-Ile-Tyr-Val-Gln-Arg.

45

Revendications

Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

50 1. Alpha-amylase chimère, qui est thermostable et manifeste un effet négatif réduit sur l'utilisation de la glucoamylase de A. niger et de la pullulanase de B. acidopullulyticus pour la saccharification de l'amidon, ayant la formule générale I

(I)

Q-R-L

dans laquelle Q comprend une partie N-terminale de 55 à 60 résidus d'aminoacides qui a une

dans laquelle

- X₁ comprend Ala-Asn-Leu ou Val,
- X₂ comprend Met ou Thr,
- X₃ comprend Ser-Ala-Tyr ou Ala-Glu-His,
- 5 X₄ comprend Ala-Gly-His ou Ser-Asp-Ile,
- X₅ comprend Thr ou Leu,
- X₆ comprend Ala ou Ser, et
- X₇ comprend Val ou Asn.

10 7. Alpha-amylase chimère selon la revendication 6, dans laquelle

- X₁ comprend Val,
- X₂ comprend Thr,
- X₃ comprend Ala-Glu-His,
- X₄ comprend Ser-Asp-Ile,
- 15 X₅ comprend Leu,
- X₆ comprend Ser, et
- X₇ comprend Asn.

20 8. Alpha-amylase selon la revendication 4, 5, 6 ou 7, dans laquelle L comprend une partie C-terminale de formule générale Ic

25

30

35

40

45

50

55

(Ic)

5 90 95 100
 Ser-Leu-His-Ser-Arg-Asp-Ile-Asn-Val-Tyr-Gly-Asp-Val
 10 105 110 115
 Val-Ile-Asn-His-Lys-Gly-Gly-Ala-Asp-Ala-Thr-Glu-Asp-Val-Thr-
 15 120 125 130
 Ala-Val-Glu-Val-Asp-Pro-Ala-Asp-Arg-Asn-Arg-Val-Ile-Ser-Gly-
 20 135 140 145
 Glu-His-Arg-Ile-Lys-Ala-Trp-Thr-His-Phe-His-Phe-Pro-Gly-Arg-
 25 150 155 160
 Gly-Ser-Thr-Tyr-Ser-Asp-Phe-Lys-Trp-His-Trp-Tyr-His-Phe-Asp-
 30 165 170 175
 Gly-Thr-Asp-Trp-Asp-Glu-Ser-Arg-Lys-Leu-Asn-Arg-Ile-Tyr-Lys-
 35 180 185 190
 Phe-Gln-Gly-Lys-Ala-Trp-Asp-Trp-Glu-Val-Ser-Asn-Glu-Asn-Gly-
 40 195 200 205
 Asn-Tyr-Asp-Tyr-Leu-Met-Tyr-Ala-Asp-Ile-Asp-Tyr-Asp-His-Pro-
 45 210 215 220
 Asp-Val-Ala-Ala-Glu-Ile-Lys-Arg-Trp-Gly-Thr-Trp-Tyr-Ala-Asn-
 50 225 230 235
 Glu-Leu-Gln-Leu-Asp-Gly-Phe-Arg-Leu-Asp-Ala-Val-Lys-His-Ile-
 55 240 245 250
 Lys-Phe-Ser-Phe-Leu-Arg-Asp-Trp-Val-Asn-His-Val-Arg-Glu-Lys-
 60 255 260 265
 Thr-Gly-Lys-Glu-Met-Phe-Thr-Val-Ala-Glu-Tyr-Trp-Gln-Asn-Asp-
 65 270 275 280
 Leu-Gly-Ala-Leu-Glu-Asn-Tyr-Leu-Asn-Lys-Thr-Asn-Phe-Asn-His-
 70 285 290 285
 Ser-Val-Phe-Asp-Val-Pro-Leu-His-Tyr-Gln-Phe-His-Ala-Ala-Ser-
 75 300 305 310
 Thr-Gln-Gly-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr-

315 320 325
Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-

330 335 340
⁵ **His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Glu-Ser-Thr-Val-Gln-Thr-**

345 350 355
Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-

10 360 365 370
Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-

375 380 385
¹⁵ **Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Glu-Pro-**

390 395 400
Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-

405 410 415
²⁰ **Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-**

420 425 430
Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-

435 440 445
²⁵ **Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-**

450 455 460
³⁰ **Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-**

465 470 475
Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-

480 483
³⁵ **Val-Ser-Ile-Tyr-Val-Gln-Arg.**

⁴⁰ 9. Procédé de production d'une alpha-amylase chimère dans lequel:

- (a) on effectue la recombinaison *in vivo* de la région codante N-terminale du gène de l'alpha-amylase de *B. amyloliquefaciens* avec la région codante C-terminale du gène de l'alpha-amylase de *B. licheniformis* pour former des recombinés;
- (b) on sélectionne les recombinés qui produisent une alpha-amylase chimère qui est thermostable et manifeste un effet négatif réduit sur l'utilisation de la glucoamylase d'*A. niger* et de la pullulanase de *B. acidopulluliticus* pour la saccharification de l'amidon;
- (c) on cultive les recombinés sélectionnés dans un milieu de croissance approprié, et
- (d) on récupère l'alpha-amylase chimère à partir de la culture.

⁵⁰ 10. Procédé de conversion d'amidon en sirop à haute teneur en dextrose, dans lequel:

- (a) on fait réagir de l'amidon avec l'alpha-amylase chimère de la revendication 1, 2, 3, 4, 5, 6 ou 7 pour former des oligosaccharides; et
- (b) on fait réagir les oligosaccharides formés dans l'étape (a) avec une glucoamylase pour former du dextrose.

⁵⁵ 11. Procédé de conversion d'amidon en sirop à haute teneur en dextrose, selon lequel:

- (a) on fait réagir de l'amidon avec l'alpha-amylase chimère de la revendication 8 pour former des oligosaccharides; et

(b) on fait réagir les oligosaccharides formés dans l'étape (a) avec une glucoamylase pour former du dextrose.

Revendications pour les Etats contractants suivants : AT, ES, GR

5

1. Procédé pour la production d'une alpha-amylase chimère comprenant :

(a) la recombinaison in vivo de la région codante N-terminale du gène de l'alpha-amylase de B. amyloliquefaciens avec la région codante C-terminale du gène de l'alpha-amylase de B. licheniformis pour former des recombinés ;

10

(b) la sélection des recombinés qui produisent une alpha-amylase chimère qui est thermostable et manifeste un effet négatif réduit sur l'utilisation de la glucoamylase d'A. niger et de la pullulanase de B. acidopullulyticus pour la saccharification de l'amidon ;

(c) la mise en culture des recombinés sélectionnés dans un milieu de croissance approprié, et

(d) la récupération de l'alpha-amylase chimère de la culture.

15

2. Procédé pour la conversion d'amidon en sirop à forte teneur en dextrose, comprenant :

(a) la mise en réaction de l'amidon avec une alpha-amylase chimère qui est thermostable et manifeste un effet négatif réduit sur l'utilisation de la glucoamylase d'A. niger et de la pullulanase de B. acidopullulyticus ayant la formule générale I

20

(I)

Q-R-L

25

dans laquelle

Q comprend une partie N-terminale de 55 à 60 résidus d'aminoacides qui a une homologie d'au moins 75 % avec les 55 résidus d'aminoacides N-terminaux de l'alpha-amylase de Bacillus amyloliquefaciens telle que décrite dans Takkinen et al., J. Biol. Chem. 258 (1983) 1007-1013 ;

30

R comprend une partie de formule générale Ia

(Ia)

58

60

70

Pro-Tyr-Asp-Leu-Tyr-Asp-Leu-Gly-Glu-Phe-X₈-Gln-Lys-

80

Gly-Thr-Val-Arg-Thr-Lys-Tyr-Gly-Thr-Lys-X₉-Glu-Leu

88

Gln-X₁₀-Ala-Ile-Lys

45

dans laquelle

X₈ comprend His ou Gln,

X₉ comprend Gly ou Ser,

X₁₀ comprend Ser ou Asp ; et

50

L comprend une partie C-terminale de 390 à 400 résidus d'aminoacides qui a une homologie d'au moins 75 % avec les 395 résidus d'aminoacides C-terminaux de l'alpha-amylase de Bacillus licheniformis 584 (ATCC 27811), pour former des oligosaccharides ; et

(b) on met en réaction les oligosaccharides formés dans l'étape (a) avec une glucoamylase pour former du dextrose.

55

3. Procédé selon la revendication 2, dans lequel dans l'alpha-amylase chimère,

X₈ comprend His,

X₉ comprend Gly, et

X₁₀ comprend Ser.

4. Procédé selon la revendication 2, dans lequel dans l'alpha-amylase chimère,

X_8 comprend Gln,
 X_9 comprend Ser, et
 X_{10} comprend Asp.

5. Procédé selon la revendication 2, dans lequel dans l'alpha-amylase chimère, les homologies sont d'au moins 80 %.

10. Procédé selon la revendication 2, dans lequel dans l'alpha-amylase chimère, les homologies sont d'au moins 90 %.

15. Procédé selon la revendication 2, dans lequel dans l'alpha-amylase chimère, Q comprend une partie N-terminale de formule générale Ib

(Ib)

5

10

15

 X_1 -Asn-Gly-Thr-Leu-Met-Gln-Tyr-Phe-Glu-Trp-Tyr-X₂-Pro-Asn-

20

25

30

35

Asp-Gly-Gln-His-Trp-Lys-Arg-Leu-Gln-Asn-Asp-X₃-Leu-X₄-Gly-

40

45

50

Ile-Thr-Ala-Val-Trp-Ile-Pro-Pro-Ala-Tyr-Lys-Gly-X₅-Ser-Gln-

55

X₆-Asp-X₇-Gly-Tyr-Gly:

30. dans laquelle

X_1 comprend Ala-Asn-Leu ou Val,
 X_2 comprend Met ou Thr,
 X_3 comprend Ser-Ala-Tyr ou Ala-Glu-His,
 X_4 comprend Ala-Gly-His ou Ser-Asp-Ile,
 X_5 comprend Thr ou Leu,
 X_6 comprend Ala ou Ser, et
 X_7 comprend Val ou Asn.

8. Procédé selon la revendication 7, dans lequel, dans l'alpha-amylase chimère,

40. X_1 comprend Val,
 X_2 comprend Thr,
 X_3 comprend Ala-Glu-His,
 X_4 comprend Ser-Asp-Ile,
 X_5 comprend Leu,
45. X_6 comprend Ser, et
 X_7 comprend Asn.

9. Procédé pour la conversion d'amidon en sirop à forte teneur en dextrose, comprenant :

50. (a) la mise en réaction de l'amidon avec une alpha-amylase chimère pour former des oligosaccharides ; et
(b) la mise en réaction des oligosaccharides formés à l'étape (a) avec une glucoamylase pour former du dextrose, l'alpha-amylase chimère étant telle que définie dans les revendications 5, 6, 7 ou 8 et dans laquelle L comprend une partie C-terminale de formule générale Ic

(Ic)

300 305 310

Thr-Gln-Gly-Gly-Gly-Tyr-Asp-Met-Arg-Lys-Leu-Leu-Asn-Ser-Thr

315 320 325

5 Val-Val-Ser-Lys-His-Pro-Leu-Lys-Ala-Val-Thr-Phe-Val-Asp-Asn-

330 335 340

His-Asp-Thr-Gln-Pro-Gly-Gln-Ser-Leu-Clu-Ser-Thr-Val-Gln-Thr-

345 350 355

10 Trp-Phe-Lys-Pro-Leu-Ala-Tyr-Ala-Phe-Ile-Leu-Thr-Arg-Glu-Ser-

360 365 370

Gly-Tyr-Pro-Gln-Val-Phe-Tyr-Gly-Asp-Met-Tyr-Gly-Thr-Lys-Gly-

375 380 385

Asp-Ser-Gln-Arg-Glu-Ile-Pro-Ala-Leu-Lys-His-Lys-Ile-Clu-Pro-

390 395 400

20 Ile-Leu-Lys-Ala-Arg-Lys-Gln-Tyr-Ala-Tyr-Gly-Ala-Gln-His-Asp-

405 410 415

Tyr-Phe-Asp-His-His-Asp-Ile-Val-Gly-Trp-Thr-Arg-Glu-Gly-Asp-

420 425 430

25 Ser-Ser-Val-Ala-Asn-Ser-Gly-Leu-Ala-Ala-Leu-Ile-Thr-Asp-Gly-

435 440 445

30 Pro-Gly-Gly-Ala-Lys-Arg-Met-Tyr-Val-Gly-Arg-Gln-Asn-Ala-Gly-

450 455 460

Glu-Thr-Trp-His-Asp-Ile-Thr-Gly-Asn-Arg-Ser-Glu-Pro-Val-Val-

465 470 475

35 Ile-Asn-Ser-Glu-Gly-Trp-Gly-Glu-Phe-His-Val-Asn-Gly-Gly-Ser-

480 483


40 Val-Ser-Ile-Tyr-Val-Gln-Arg.

40

45


50

55



B. LICHENIFORMIS

B. AMYLOLIQUEFACIENS



QL1864

FIG. 1




FIG. 2




FIG. 3




FIG. 4